CSChristopher K. Surratt

Christopher K. Surratt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christopher K. Surratt has a total of 92 co-authors. Here are the top co-authors by number of shared publications:

  • Jeffry D. Madura

    Department of Chemistry and Biochemistry, Center for Computational Sciences, Duquesne University , Pittsburgh, Pennsylvania 15282, United States

    7 shared publications
  • Laura M. Geffert

    Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, USA

    3 shared publications
  • Okechukwu T. Ukairo

    Duquesne University

    3 shared publications
  • Suneetha Ramanujapuram

    Duquesne University

    3 shared publications
  • J. Douglas Bricker

    Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA 15282

    2 shared publications
  • Jeffry D. Madura

    Department of Chemistry and Biochemistry, Duquesne University, Pittsburgh, PA 15282, United States

    2 shared publications

Latest Publications

  • Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via transporter-based virtual screening

    by Jeffery N. Talbot, Laura M. Geffert, Jessica E. Jorvig, Ruben I. Goldstein, Cienna L. Nielsen, Nicholas E. Wolters, Mary Ellen Amos, Caitlin A. Munro, Elizabeth Dallman, Maddalena Mereu, et al.


  • Open Access

    Editorial: In silico Modeling of Brain Receptors for Antidepressants, Psychostimulants, and Other CNS-Active Drugs

    by Christopher K. Surratt, Jeffry D. Madura

    Editorial: In silico Modeling of Brain Receptors for Antidepressants, Psychostimulants, and Other CNS-Active Drugs

  • Open Access

    A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets

    by Michael J. Wasko, Kendy A. Pellegrene, Jeffry D. Madura, Christopher K. Surratt

    Hundreds of millions of U.S. dollars are invested in the research and development of a single drug. Lead compound development is an area ripe for new design strategies. Therapeutic lead candidates have been traditionally found using high-throughput in vitro pharmacologic screening, a costly method for assaying thousands of compounds. This approach has recently been augmented by virtual screening, which employs computer models of the target protein to narrow the search for possible leads. A variant of virtual screening is fragment-based drug design, an emerging in silico lead discovery method that introduces low molecular weight fragments, rather than intact compounds, into the binding pocket of the receptor model. These fragments serve as starting points for “growing” the lead candidate. Current efforts in virtual fragment-based drug design within central nervous system (CNS) targets are reviewed, as is a recent rule-based optimization strategy in which new molecules are generated within a 3D receptor binding pocket using the fragment as a scaffold. This process places special emphasis on creating synthesizable molecules but also exposes computational questions worth addressing. Fragment-based methods provide a viable, relatively low-cost alternative for therapeutic lead discovery and optimization that can be applied to CNS targets to augment current design strategies.


  • Open Access

    Discovery of Novel-Scaffold Monoamine Transporter Ligands via in Silico Screening with the S1 Pocket of the Serotonin Transporter

    by Tammy L. Nolan, Laura M. Geffert, Benedict J. Kolber, Jeffry D. Madura, Christopher K. Surratt

    Discovery of new inhibitors of the plasmalemmal monoamine transporters (MATs) continues to provide pharmacotherapeutic options for depression, addiction, attention deficit disorders, psychosis, narcolepsy, and Parkinson’s disease. The windfall of high-resolution MAT structural information afforded by X-ray crystallography has enabled the construction of credible computational models. Elucidation of lead compounds, creation of compound structure–activity series, and pharmacologic testing are staggering expenses that could be reduced by using a MAT computational model for virtual screening (VS) of structural libraries containing millions of compounds. Here, VS of the PubChem small molecule structural database using the S1 (primary substrate) ligand pocket of a serotonin transporter homology model yielded 19 prominent “hit” compounds. In vitro pharmacology of these VS hits revealed four structurally unique MAT substrate uptake inhibitors with high nanomolar affinity at one or more of the three MATs. In vivo characterization of three of these hits revealed significant activity in a mouse model of acute depression at doses that did not elicit untoward locomotor effects. This constitutes the first report of MAT inhibitor discovery using exclusively the primary substrate pocket as a VS tool. Novel-scaffold MAT inhibitors offer hope of new medications that lack the many classic adverse effects of existing antidepressant drugs.


  • New design strategies for antidepressant drugs

    by Kalyan Immadisetty, Laura M Geffert, Christopher K Surratt, Jeffry D Madura

    Introduction: In spite of research efforts spanning six decades, the most prominent antidepressant drugs to date still carry several adverse effects, often serious enough to warrant discontinuation of the drug. Molecular mechanisms of depression are now better understood such that some of the specific receptors responsible can be targeted for activation or inhibition. This advance, coupled with the recent availability of crystal structures of relevant drug targets or their homologs, has opened the door for new antidepressant therapeutic compounds. Areas covered: The authors review the evolution of monoamine-based antidepressant drugs, up to the selective serotonin reuptake inhibitors (SSRIs). The authors discuss classic and contemporary antidepressant drug design strategies, with a focus on virtual screening and fragment-based drug design methods. Furthermore, they discuss the recent advancements in the understanding of the serotonin transporter (SERT) structure/function relationship in the context of recognition of SSRIs and outline a strategy for the use of computational approaches in producing new SSRI lead compounds. Expert opinion: The authors suggest that given the long-awaited availability of credible three-dimensional structures for the SERT and related monoamine transporter proteins, cutting-edge computational methods should be the linchpin of future drug discovery efforts regarding monoamine-based antidepressant lead compounds. Because these transporter inhibitors cause a ubiquitous increase in extraneuronal neurotransmitter levels leading to side and adverse therapeutic effects, the drug discovery should extend to appropriate manipulation of the ‘downstream' receptors affected by the neurotransmitter boost. Efficient use of new computational strategies will accelerate the drug discovery process and reduce its economic burden.


  • Identification of a Novel Selective Serotonin Reuptake Inhibitor by Coupling Monoamine Transporter-Based Virtual Screening and Rational Molecular Hybridization

    by Tammy L. Nolan, David J. Lapinsky, Jeffery N. Talbot, Martín Indarte, Yi Liu, Sankar Manepalli, Laura M. Geffert, Mary Ellen Amos, Phillip N. Taylor, Jeffry D. Madura, et al.

    Ligand virtual screening (VS) using the vestibular binding pocket of a three-dimensional (3-D) monoamine transporter (MAT) computational model followed by in vitro pharmacology led to the identification of a human serotonin transporter (hSERT) inhibitor with modest affinity (hSERT Ki = 284 nM). Structural comparison of this VS-elucidated compound, denoted MI-17, to known SERT ligands led to the rational design and synthesis of DJLDU-3-79, a molecular hybrid of MI-17 and dual SERT/5-HT1A receptor antagonist SSA-426. Relative to MI-17, DJLDU-3-79 displayed 7-fold improvement in hSERT binding affinity and a 3-fold increase in [3H]-serotonin uptake inhibition potency at hSERT-HEK cells. This hybrid compound displayed a hSERT:hDAT selectivity ratio of 50:1 and a hSERT:hNET (human norepinephrine transporter) ratio of >200:1. In mice, DJLDU-3-79 decreased immobility in the tail suspension test comparable to the SSRI fluvoxamine, suggesting that DJLDU-3-79 may possess antidepressant properties. This proof of concept study highlights MAT virtual screening as a powerful tool for identifying novel inhibitor chemotypes and chemical fragments for rational inhibitor design.


  • Receptor-Based Discovery of a Plasmalemmal Monoamine Transporter Inhibitor via High-Throughput Docking and Pharmacophore Modeling

    by Martín Indarte, Yi Liu, Jeffry D. Madura, Christopher K. Surratt

    Recognition of psychostimulants such as cocaine and the amphetamines by the dopamine transporter (DAT) protein is principally responsible for the euphoria and addiction associated with these drugs. Using as a template the crystal structure of a distantly related bacterial leucine transporter, we have generated 3-D DAT computer molecular models. Ligand docking to such models has revealed potential substrate and inhibitor binding pockets, subsequently confirmed by in vitro pharmacology. An inhibitor pocket defined by the DAT model to be within the “extracellular vestibule”, just to the extracellular side of the external gate of the primary substrate pocket, was used for virtual screening of a structural library of compounds. High-throughput docking and application of pharmacophore constraints within this vestibular inhibitor pocket identified a compound structurally dissimilar to the classic monoamine (dopamine, norepinephrine, and serotonin) transporter (MAT) inhibitors. The compound displaced binding of radiolabeled cocaine analogs at all three MATs, usually with nanomolar Ki values and within 2-fold of cocaine’s affinity at the norepinephrine transporter. Although a very weak dopamine uptake inhibitor itself, this compound reduced by 3-fold the potency of cocaine in inhibiting DAT-mediated cellular uptake of dopamine. To our knowledge, the present findings are the first to successfully employ “receptor-based” computer modeling to identify moderate- to high-affinity MAT ligands. In silico ligand screening using MAT models provides a rapid, low-cost discovery process that should accelerate identification of novel ligand scaffolds and provide lead compounds in combating psychostimulant addiction and in treating other monoamine-related CNS diseases.


  • Dopamine transporter comparative molecular modeling and binding site prediction using the LeuTAaleucine transporter as a template

    by Martín Indarte, Jeffry D. Madura, Christopher K. Surratt

    Pharmacological and behavioral studies indicate that binding of cocaine and the amphetamines by the dopamine transporter (DAT) protein is principally responsible for initiating the euphoria and addiction associated with these drugs. The lack of an X‐ray crystal structure for the DAT or any other member of the neurotransmitter:sodium symporter (NSS) family has hindered understanding of psychostimulant recognition at the atomic level; structural information has been obtained largely from mutagenesis and biophysical studies. The recent publication of a crystal structure for the bacterial leucine transporter LeuTAa, a distantly related NSS family homolog, provides for the first time a template for three‐dimensional comparative modeling of NSS proteins. A novel computational modeling approach using the capabilities of the Molecular Operating Environment program MOE 2005.06 in conjunction with other comparative modeling servers generated the LeuTAa‐directed DAT model. Probable dopamine and amphetamine binding sites were identified within the DAT model using multiple docking approaches. Binding sites for the substrate ligands (dopamine and amphetamine) overlapped substantially with the analogous region of the LeuTAacrystal structure for the substrate leucine. The docking predictions implicated DAT side chains known to be critical for high affinity ligand binding and suggest novel mutagenesis targets in elucidating discrete substrate and inhibitor binding sites. The DAT model may guide DAT ligand QSAR studies, and rational design of novel DAT‐binding therapeutics. Proteins 2008.